Patents by Inventor Jan Markussen
Jan Markussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9260501Abstract: Insulins to which there is connected an amino acid oligomer have satisfactory properties.Type: GrantFiled: October 29, 2007Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Thomas Høeg-Jensen, Thomas Børglum Kjeldsen, Jan Markussen
-
Patent number: 8835132Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: GrantFiled: August 18, 2009Date of Patent: September 16, 2014Assignee: Novo Nordisk A/SInventors: Ib Jonassen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
-
Publication number: 20100069605Abstract: Insulins to which there is connected an amino acid oligomer have satisfactory properties.Type: ApplicationFiled: October 29, 2007Publication date: March 18, 2010Applicant: Novo Nordisk A/SInventors: Thomas Høeg-Jensen, Thomas Børglum Kjeldsen, Jan Markussen
-
Publication number: 20100055738Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: ApplicationFiled: August 18, 2009Publication date: March 4, 2010Applicant: Novo Nordisk A/SInventors: Ib Jonassen, Michi Egel- Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
-
Patent number: 7595172Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: GrantFiled: July 24, 2002Date of Patent: September 29, 2009Assignee: Novo Nordisk A/SInventors: Ib Jonassen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
-
Patent number: 7572884Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: GrantFiled: July 28, 2005Date of Patent: August 11, 2009Assignee: Novo Nordisk A/SInventors: Thomas Hoeg-Jensen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers
-
Patent number: 7402565Abstract: A method is provided which allows high yields of acylated insulin. The method comprises expressing a singe-chain insulin precursor, preferably in yeast, cleaving the single-chain insulin precursor with a suitable protease which will open the peptide bond between the C-terminal amino group in the B-chain and a connecting peptide connecting the B chain with the A-chain, acylating the two-chain insulin intermediate in the ?-amino group in LysB29 and subjecting the acylated two-chain insulin intermediate to a proteolytic enzyme which will cleave of the N-terminal extension on the B- and A-chains on the precursor molecule.Type: GrantFiled: May 3, 2006Date of Patent: July 22, 2008Assignee: Novo Nordisk A/SInventors: Thomas Børglum Kjeldsen, Jan Markussen
-
Patent number: 7317000Abstract: The present invention relates to insulin derivatives having a built-in glucose sensor and a polyol moiety, capable to deliver insulin from an injected depot of an insulin derivative according to the invention as a function of the glucose concentration in the surrounding tissue.Type: GrantFiled: December 2, 2002Date of Patent: January 8, 2008Assignee: Novo Nordisk A/SInventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen
-
Patent number: 7316999Abstract: Insulin derivatives having a built-in glucose sensor, capable of delivering insulin from a depot as a function of the glucose concentration in the surrounding medium (e.g. tissue), such that the rate of insulin release from the depot increases with an increased glucose concentration and decreases with a decreased glucose concentration.Type: GrantFiled: May 31, 2001Date of Patent: January 8, 2008Assignee: Novo Nordisk A/SInventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen, Soren Ostergaard, Signe Ridderberg, Per Balschmidt, Lauge Schaffer, Ib Jonassen
-
Patent number: 7229964Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: July 16, 2003Date of Patent: June 12, 2007Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Publication number: 20060264606Abstract: A method is provided which allows high yields of acylated insulin. The method comprises expressing a singe-chain insulin precursor, preferably in yeast, cleaving the single-chain insulin precursor with a suitable protease which will open the peptide bond between the C-terminal amino group in the B-chain and a connecting peptide connecting the B chain with the A-chain, acylating the two-chain insulin intermediate in the ?-amino group in LysB29 and subjecting the acylated two-chain insulin intermediate to a proteolytic enzyme which will cleave of the N-terminal extension on the B- and A-chains on the precursor molecule.Type: ApplicationFiled: May 3, 2006Publication date: November 23, 2006Applicant: Novo Nordisk A/SInventors: Thomas Kjeldsen, Jan Markussen
-
Publication number: 20060030518Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the C-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.Type: ApplicationFiled: June 28, 2005Publication date: February 9, 2006Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Andersen, Jan Markussen
-
Publication number: 20060003421Abstract: Process for purifying a fermentation-derived product.Type: ApplicationFiled: September 6, 2005Publication date: January 5, 2006Applicant: Novo Nordisk A/SInventors: Jan Markussen, Ivan Diers
-
Publication number: 20050272125Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: ApplicationFiled: July 28, 2005Publication date: December 8, 2005Inventors: Thomas Hoeg-Jensen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers
-
Patent number: 6869930Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ?-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.Type: GrantFiled: September 17, 1999Date of Patent: March 22, 2005Assignee: Novo Nordisk A/SInventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
-
Publication number: 20040137571Abstract: Process for purifying a fermentation-derived product.Type: ApplicationFiled: November 21, 2003Publication date: July 15, 2004Inventors: Jan Markussen, Ivan Diers
-
Publication number: 20040110664Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the &egr;-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the &egr;-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.Type: ApplicationFiled: March 12, 2002Publication date: June 10, 2004Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
-
Publication number: 20040067874Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: ApplicationFiled: July 16, 2003Publication date: April 8, 2004Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Publication number: 20030186846Abstract: The present invention relates to insulin derivatives having a built-in glucose sensor and a polyol moiety, capable to deliver insulin from an injected depot of an insulin derivative according to the invention as a function of the glucose concentration in the surrounding tissue.Type: ApplicationFiled: December 2, 2002Publication date: October 2, 2003Inventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen
-
Patent number: 6620780Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: May 21, 2001Date of Patent: September 16, 2003Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm